Research programme: antibody drug conjugates- Centre for the Commercialization of Antibodies and Biologics/ ImmunoBiochem Corporation
Latest Information Update: 22 Apr 2016
At a glance
- Originator Centre for the Commercialization of Antibodies and Biologics; ImmunoBiochem
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours